A repurposed vitamin D drug is showing early promise in reshaping the battlefield against one of the deadliest cancers. In a new clinical trial, researchers at the Dana-Farber Cancer Institute found that adding a synthetic vitamin D analog called paricalcitol to standard chemotherapy helped reprogram the dense, protective tissue surrounding pancreatic tumors, potentially making them more vulnerable to treatment.
Pancreatic ductal adenocarcinoma is notoriously difficult to treat because its tumors are encased in a thick, fibrous shell built by cells called cancer-associated fibroblasts. This stroma acts as a physical and immune barrier, blocking chemotherapy drugs and immune cells from reaching the cancer. The phase 1 trial enrolled 36 patients with metastatic pancreatic cancer who had not received prior treatment. They received standard chemotherapy with gemcitabine and nab-paclitaxel, plus either oral or intravenous paricalcitol or a placebo. The primary goal was to test safety and tolerability.
The results, published in Nature Cancer, showed that paricalcitol was generally safe, though some patients on the oral form developed manageable hypercalcemia. More importantly, analysis of tumor biopsies taken before and during treatment revealed that paricalcitol reprogrammed fibroblasts rather than eliminating them. This shift reduced fibrosis and was linked to a 42% partial tumor response rate in the paricalcitol groups, compared to 9% in the placebo group. One-year progression-free survival also favored those receiving the vitamin D analog. Patients whose tumors had high levels of the vitamin D receptor before treatment appeared to benefit most, suggesting the receptor could serve as a biomarker for selecting candidates for this approach.
From Laboratory Insight to Clinical Strategy
The trial builds on foundational research by Salk Institute Professor Ronald Evans, whose discovery of the nuclear receptor superfamily showed how molecules like the vitamin D receptor regulate gene expression in response to hormones and vitamins. Earlier studies had found that vitamin D receptors are abundant on certain fibroblast subsets that maintain organ health. Synthetic analogs like paricalcitol, already FDA-approved for kidney disease, were shown to reduce fibrosis and inflammation by altering fibroblast activity. This insight led researchers to test whether the same mechanism could break down the stromal fortress around pancreatic tumors.
By pharmacologically “re-educating” fibroblasts, the vitamin D analog transforms the tumor microenvironment from a hostile, immunosuppressive zone into one more permissive for immune cell infiltration and drug delivery. This represents a shift from focusing solely on killing cancer cells to also modifying the supportive architecture that protects them. The approach could have implications for other cancers driven by fibrosis.
Larger trials are now being planned to confirm survival benefits and refine patient selection using vitamin D receptor levels as a guide. Researchers also aim to test paricalcitol in combination with immunotherapies, such as checkpoint inhibitors, to see if stromal remodeling can unlock immune responses against pancreatic cancer. While challenges remain, including optimizing dosing and understanding long-term effects, this study offers a hopeful new direction for a disease that has long resisted progress. It shows that by harnessing the body’s own regulatory systems, scientists may finally be finding ways to dismantle pancreatic cancer’s defenses from the inside out.